Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells
Yeni Romero, Randi Wise, Anna Żółkiewska
Cancer Immunology Immunotherapy (2019) Vol. 69, Iss. 1, pp. 43-55
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Hirohito Yamaguchi, Jung-Mao Hsu, Wenhao Yang, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 5, pp. 287-305
Closed Access | Times Cited: 328
Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 262
PD-L1 degradation pathway and immunotherapy for cancer
Qian Gou, Dong Chen, Huihui Xu, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 193
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 92
The B7:CD28 family and friends: Unraveling coinhibitory interactions
Kelly P. Burke, Apoorvi Chaudhri, Gordon J. Freeman, et al.
Immunity (2024) Vol. 57, Iss. 2, pp. 223-244
Open Access | Times Cited: 30
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 96
Targeting ADAM10 in Cancer and Autoimmunity
Timothy M. Smith, Anuj Tharakan, Rebecca Martin
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 89
Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution
Matteo Calligaris, Doretta Cuffaro, Simone Bonelli, et al.
Molecules (2021) Vol. 26, Iss. 4, pp. 944-944
Open Access | Times Cited: 85
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Kaijian Zhou, Shu Guo, Fei Li, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 76
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy
Wenjun Xiong, Yang Gao, Wenyi Wei, et al.
Trends in cancer (2021) Vol. 7, Iss. 9, pp. 837-846
Closed Access | Times Cited: 65
Soluble PD-L1 as an early marker of progressive disease on nivolumab
Kathleen M. Mahoney, Petra Ross‐Macdonald, Long Yuan, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e003527-e003527
Open Access | Times Cited: 57
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, et al.
Genes & Diseases (2022) Vol. 10, Iss. 4, pp. 1318-1350
Open Access | Times Cited: 51
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Yazhen Wang, Zhou Yang, Lianyi Yang, et al.
Advanced Science (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 23
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
New insights into the function and pathophysiology of the ectodomain sheddase A Disintegrin And Metalloproteinase 10 (ADAM10)
David P. Rosenbaum, Paul Säftig
FEBS Journal (2023) Vol. 291, Iss. 13, pp. 2733-2766
Open Access | Times Cited: 22
Inhibition of CK2/ING4 Pathway Facilitates Non‐Small Cell Lung Cancer Immunotherapy
Qian Gou, Huiqing Chen, Mingjun Chen, et al.
Advanced Science (2023) Vol. 10, Iss. 34
Open Access | Times Cited: 17
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
Jacob J. Orme, Elizabeth Ann L. Enninga, Fabrice Lucien-Matteoni, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001113-e001113
Open Access | Times Cited: 47
NKG2D Ligand Shedding in Response to Stress: Role of ADAM10
Alessandra Zingoni, Elisabetta Vulpis, Luisa Loconte, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 45
Immunomodulatory role of metalloproteinase ADAM17 in tumor development
Kai Wang, Zixue Xuan, Xiaoyan Liu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
New insight into the role of the ADAM protease family in breast carcinoma progression
Sepideh Aliniaye Navasatli, Saeed Niazi Vahdati, Tahura Fayeghi Arjmand, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e24805-e24805
Open Access | Times Cited: 5
Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment
Tiecheng Wang, Jiakang Jin, Chao Qian, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 27
Suppression of PD‐L1 release from small extracellular vesicles promotes systemic anti‐tumor immunity by targeting ORAI1 calcium channels
Xi Chen, Jiaqi Li, Ren Zhang, et al.
Journal of Extracellular Vesicles (2022) Vol. 11, Iss. 12
Open Access | Times Cited: 20
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients
Giulia Pasello, Aline S.C. Fabricio, Paola Del Bianco, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
Proteolytic Factors in the Tumor Immune Microenvironment
Yuuki Nishimura, Miku Maeda, Hoshiho Kubota, et al.
(2025), pp. 1-18
Closed Access
Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms
Glazanova Tv, Irina Pavlovа, E. V. Kuzmich, et al.
Medical Immunology (Russia) (2025) Vol. 27, Iss. 1, pp. 21-34
Open Access
Page 1 - Next Page

Scroll to top